Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma
暂无分享,去创建一个
R. Dummer | J. Larkin | J. Sosman | J. Kirkwood | P. Hersey | L. Bastholt | C. Robert | M. Middleton | V. Zazulina | K. Kemsley | M. Cantarini
[1] T. Ciuleanu,et al. A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy , 2012, Investigational New Drugs.
[2] D. Schadendorf,et al. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). , 2011, European journal of cancer.
[3] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[4] K. Flaherty,et al. Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] K. Flaherty,et al. BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] C. Ng,et al. Clinical characteristics and outcomes associated with BRAF and NRAS mutations in metastatic melanoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] G. Mann,et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] J. Choi,et al. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta‐analysis , 2011, The British journal of dermatology.
[9] Stephen L. Abrams,et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health , 2011, Oncotarget.
[10] G. Ellison,et al. A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples , 2010, Journal of experimental & clinical cancer research : CR.
[11] K. Flaherty,et al. Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.
[12] M. Brown,et al. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. , 2010 .
[13] K. Flaherty,et al. Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212. , 2010 .
[14] A. Lazar,et al. Clinical responses to AZD6244 (ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma. , 2010 .
[15] B. Taylor,et al. Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). , 2010, Cancer research.
[16] Paul D. Smith,et al. The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer , 2010, Clinical Cancer Research.
[17] L. French,et al. Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibition Results in Biphasic Alteration of Epidermal Homeostasis with Keratinocytic Apoptosis and Pigmentation Disorders , 2010, Clinical Cancer Research.
[18] W. T. van der Graaf,et al. Case studies showing clinical signs and management of cutaneous toxicity of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in patients with solid tumours , 2010, Acta oncologica.
[19] D. Rimm,et al. C-Raf Is Associated with Disease Progression and Cell Proliferation in a Subset of Melanomas , 2009, Clinical Cancer Research.
[20] Paul D. Smith,et al. 265 POSTER A MEK1/2 inhibitor, AZD6244 (ARRY-142886), shows beneficial effects when combined with standards of care or novel therapies – mechanistic characterisation suggests a role for apoptosis , 2008 .
[21] Chunrong Yu,et al. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. , 2008, Cancer research.
[22] G. Pond,et al. Influence of an independent review committee on assessment of response rate and progression-free survival in phase III clinical trials. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] W. Franklin,et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] J. Hansson,et al. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site , 2008, Molecular oncology.
[25] P. LoRusso,et al. Clinical experience of MEK inhibitors in cancer therapy. , 2007, Biochimica et biophysica acta.
[26] Paul D. Martin,et al. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models , 2007, Molecular Cancer Therapeutics.
[27] G. Tzivion,et al. Raf kinases: function, regulation and role in human cancer. , 2007, Biochimica et biophysica acta.
[28] Suzanne Schubbert,et al. Hyperactive Ras in developmental disorders and cancer , 2007, Nature Reviews Cancer.
[29] Kenichi Nomoto,et al. Recent advances of MEK inhibitors and their clinical progress. , 2007, Current topics in medicinal chemistry.
[30] Vivienne Marsh,et al. Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor , 2007, Clinical Cancer Research.
[31] G. Kéri,et al. Signaling through RAS-RAF-MEK-ERK: from basics to bedside. , 2007, Current medicinal chemistry.
[32] D. Schadendorf,et al. Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] Boris Freidlin,et al. Design issues of randomized phase II trials and a proposal for phase II screening trials. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] E. Van Cutsem,et al. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[35] N. Hayward,et al. Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS , 2005, British Journal of Cancer.
[36] R. Simon,et al. Evaluating the Efficiency of Targeted Designs for Randomized Clinical Trials , 2004, Clinical Cancer Research.
[37] D. Barford,et al. Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.
[38] K. Hemminki,et al. Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9 , 2003, Oncogene.
[39] L. Kanter,et al. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[40] L. Kanter,et al. Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[41] M. Ziepert,et al. Reply to K. Tay et al , 2011 .
[42] R. Weichselbaum,et al. Predictors of competing mortality in advanced head and neck cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] G. Robertson,et al. Is B-Raf a good therapeutic target for melanoma and other malignancies? , 2008, Cancer research.
[44] D. Schadendorf,et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.